Patents on β-lactam antibacterials: January 1999 to March 2001

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 8, 2001, Pages 1267-1276

  Kim, O K ^a   Fung Tomc, J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

lactam antibacterials; Carbapenems (penems); Cephalosporins (cephems); Methicillin resistant coagulase negative Staphylococci (MRCNS); Methicillin resistant Staphylococcus aureus (MRSA)

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFALEXIN; CEFDINIR; CEFOTAXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; HETEROCYCLIC COMPOUND; IMIPENEM; MEROPENEM; OXAZOLIDINONE DERIVATIVE; PANIPENEM; PYRROLIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PATENT; REVIEW;

EID: 0034904741     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.8.1267     Document Type: Review

References (18)

1. Cephems: Fifty years of continuous research
2. Modern β-lactam antibiotics
3. Interplay of impermeability and chromosomal β-lactamase in imipenem-resistant Pseudomonas aeruginosa
4. Contribution of the MexAB-OprM multidrug efflux system to the beta-lactam resistance of penicillin-binding protein and beta-lactamase-derepressed mutants of Pseudomonas aeruginosa
5. Evolution and dissemination of β-lactamases accelerated by generation of β-lactam antibiotics
6. Successful interventions for Gram-negative resistance to extended-spectrum β-lactam antibiotics
7. Carbapenemases: A problem in waiting
8. National Committee for Clinical Laboratory Standards (NCCLS): Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
9. New β-lactamases in Gram-negative bacteria: Diversity and impact on the selection of antimicrobial therapy
10. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region
11. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam
12. Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents
13. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen
14. Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications
15. The changing epidemiology of Staphylococcus aureus
16. Methicillin-resistant Staphylococcus aureus as a community organism
17. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk
18. In-vitro antimicrobial activity of a carabapenem, MK-0826 (L-749,345) and provisional interpreative criteria for disc tests